Paliperidone ER versus risperidone for neurocognitive function in patients with schizophrenia: A randomized, open-label, controlled trial

International Clinical Psychopharmacology

Volumn 27, Issue 5, 2012, Pages 267-274

  Kim, Sung Wan ^a   Chung, Young Chul ^d   Lee, Yo Han ^b   Lee, Jeong Hoon ^c   Kim, Seon Young ^a   Bae, Kyung Yeol ^a   Kim, Jae Min ^a   Shin, Il Seon ^a   Yoon, Jin Sang ^a  

^a Chonnam National University Medical School   (South Korea)

^b St John Hospital   (South Korea)

^c Gwangju City Geriatric Hospital   (South Korea)

^d Chonbuk National University Medical School   (South Korea)

Author keywords

cognitive; paliperidone; risperidone; schizophrenia; social function

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CHOLINERGIC RECEPTOR BLOCKING AGENT; PALIPERIDONE; PROPRANOLOL; RISPERIDONE;

ADULT; AKATHISIA; ARTICLE; COGNITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; HYPERPROLACTINEMIA; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; OPEN STUDY; PARKINSONISM; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SCORING SYSTEM; SOCIAL INTERACTION; TARDIVE DYSKINESIA; TREATMENT DURATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; COGNITION DISORDERS; DELAYED-ACTION PREPARATIONS; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOPAMINE ANTAGONISTS; DRUG MONITORING; FEMALE; HUMANS; ISOXAZOLES; MALE; MIDDLE AGED; MOVEMENT DISORDERS; PREVALENCE; PSYCHIATRIC STATUS RATING SCALES; PYRIMIDINES; RECEPTORS, DOPAMINE D2; REPUBLIC OF KOREA; RISPERIDONE; SCHIZOPHRENIA; YOUNG ADULT;

EID: 84864688935     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0b013e328356acad     Document Type: Article

References (43)

1. Addington D, Addington J, Schissel B (1990). A depression rating scale for schizophrenics. Schizophr Res 3:247-251. (Pubitemid 20228720)
2. American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Press Inc.
3. Barnes TR (1989). A rating scale for drug induced akathisia. Br J Psychiatry 154:672-676. (Pubitemid 19154942)
4. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J (1961). An inventory of measuring depression. Arch Gen Psychiatry 4:53-63.
5. Benton AL, Hamscher K (1978). Multilingual Aphasia Examination Manual. Revised. Iowa City: University of Iowa.
6. Canuso CM, Youssef EA, Bossie CA, Turkoz I, Schreiner A, Simpson GM (2008). Paliperidone extended-release tablets in schizophrenia patients previously treated with risperidone. Int Clin Psychopharmacol 23:209-215.
7. Canuso CM, Grinspan A, Kalali A, Damaraju CV, Merriman U, Alphs L, et al. (2010). Medication satisfaction in schizophrenia: a blinded-initiation study of paliperidone extended release in patients suboptimally responsive to risperidone. Int Clin Psychopharmacol 25:155-164.
8. De Leon J,Wynn G, Sandson NB (2010). The pharmacokinetics of paliperidone versus risperidone. Psychosomatics 51:80-88.
9. Gahr M, Kölle MA, Schönfeldt-Lecuona C, Lepping P, Freudenmann RW (2011). Paliperidone extended-release: does it have a place in antipsychotic therapy? Drug Des Devel Ther 5:125-146.
10. Guy W (1976). ECDEU Assessment manual for psychopharmacology. Washington, DC: US Department of Health, Education and Welfare. pp. 534-537.
11. Ha KS, Kwon JS, Lyoo IK, Kong SW, Lee DW, Youn T (2002). Development and standardization process, and factor analysis of the computerized cognitive function test system for Korea adults. J Korean Neuropsychiatr Assoc 41:551-562.
12. Hahn HM, Yum TH, Shin YW, Kim KH, Yoon DJ, Chung KJ (1986). Standardization study of Beck Depression Inventory in Korea. J Korean Neuropsychiatr Assoc 25:487-502.
13. Harvey PD, White L, Parrella M, Putnam KM, Kincaid MM, Powchik P, et al. (1995). The longitudinal stability of cognitive impairment in schizophrenia. Mini-mental state scores at one-and two-year follow-ups in geriatric in-patients. Br J Psychiatry 166:630-633.
14. Harvey PD, Meltzer H, Simpson GM, Potkin SG, Loebel A, Siu C, et al. (2004). Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia. Schizophr Res 66:101-113. (Pubitemid 38041108)
15. Kane J, Canas F, Kramer M, Ford L, Gassmann-Mayer C, Lim P, et al. (2007). Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res 90:147-161. (Pubitemid 46178537)
16. Kapur S, Seeman P (2001). Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry 158:360-369. (Pubitemid 32205190)
17. Kay SR, Fiszbein A, Opler LA (1987). The positive and negative syndrome scale for schizophrenia. Schizophr Bull 13:261-276. (Pubitemid 18039085)
18. Keefe RS, Sweeney JA, Gu H, Hamer RM, Perkins DO, McEvoy JP, et al. (2007). Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 164:1061-1071. (Pubitemid 47121395)
19. Kern RS, Green MF, Cornblatt BA, Owen JR, McQuade RD, Carson WH, et al. (2006). The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine. Psychopharmacology 187:312-320. (Pubitemid 44079923)
20. Kim SW, Kim SJ, Yoon BH, Kim JM, Shin IS, Hwang MY, et al. (2006). Diagnostic validity of assessment scales for depression in patients with schizophrenia. Psychiatry Res 144:57-63. (Pubitemid 44354890)
21. Kim SW, Shin IS, Kim JM, Lee SH, Lee JH, Yoon BH, et al. (2007a). Amisulpride versus risperidone in the treatment of depression in patients with schizophrenia: a randomized, open-label, controlled trial. Prog Neuropsychopharmacol Biol Psychiatry 31:1504-1509.
22. Kim SW, Shin IS, Kim JM, Yoo JA, Ahn YM, Kwon JS, et al. (2007b). A validation study of the Korean version of Subjective Well-being under Neuroleptic Treatment Scale-short form. Korean J Psychopharmacol 18:221-230.
23. Kim SW, Shin IS, Kim JM, Lee JH, Lee YH, Yang SJ, et al. (2009a). Effectiveness of switching to aripiprazole from atypical antipsychotics in patients with schizophrenia. Clin Neuropharmacol 32:243-249.
24. Kim SW, Shin IS, Kim JM, Lee SH, Lee YH, Yang SJ, et al. (2009b). Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia. Human Psychopharmacol 24:565-573.
25. Kim YK,Won SD, Lee KM, Choi HS, Jang HS, Lee BH, et al. (2005). A study on the reliability and validity of the Korean version of the Calgary Depression Scale for Schizophrenia (K-CDSS). J Korean Neuropsychiatr Assoc 44:446-455.
26. Knegtering R, Baselmans P, Kastelin C (2005). Predominant role of the 9-hydroxy-metabolite of risperidone in elevating blood prolactin-levels. Am J Psychiatry 162:1010-1012. (Pubitemid 40676220)
27. Kwon JS, Lyoo IK, Hong KS, Yeon BK, Ha KS (2002). Development and standardization of the computerized memory assessment for Korean adults. J Korean Neuropsychiatr Assoc 41:347-358.
28. Lee SW, Lee JG, Lee BJ, Kim YH (2007). A 12-week, double-blind, placebocontrolled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia. Int Clin Psychopharmacol 22:63-68.
29. Lezak MD (1995). Neuropsychological assessment. 3rd ed. New York, NY: Oxford University Press.
30. Luthringer R, Staner L, Noel N, Muzet M, Gassmann-Mayer C, Talluri K, et al. (2007). A double-blind, placebo-controlled, randomized study evaluating the effect of paliperidone extended-release tablets on sleep architecture in patients with schizophrenia. Int Clin Psychopharmacol 22:299-308. (Pubitemid 47237549)
31. Meltzer HY (2004). Cognitive factors in schizophrenia: causes, impact, and treatment. CNS Spectr 9 (Suppl 11):15-24. (Pubitemid 39473435)
32. Naber D, Moritz S, Lambert M, Pajonk FG, Holzbach R, Mass R, et al. (2001). Improvement of schizophrenic patients' subjective wellbeing under atypical antipsychotic drugs. Schizophr Res 50:79-88. (Pubitemid 32510889)
33. Pani L, Marchese G (2009). Expected clinical benefits of paliperidone extendedrelease formulation when compared with risperidone immediate-release. Expert Opin Drug Deliv 6:319-331.
34. Park CH, Park TW, Yang JC, Lee KH, Huang GB, Tong Z, et al. (2012). No negative symptoms in healthy volunteers after single doses of amisulpride, aripiprazole, and haloperidol: a double-blind placebo-controlled trial. Int Clin Psychopharmacol 27:114-120.
35. Patrick DL, Burns T, Morosini P, Gagnon DD, Rothman M, Adriaenssen I (2010). Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets. Clin Ther 32:275-292.
36. Rey A (1964). Clinical tests in psychology. Paris, France: Presses Universitaires de France.
37. Rossenu S, Cleton A, Talluri K (2007). Evaluation of the pharmacokinetics of an extended-release formulation of paliperidone with an immediate-release formulation of risperidone. Clin Pharm Ther 81 (Suppl 1):62.
38. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, et al. (1996). Risperidone compared with new and reference antipsychotic drugs: in-vitro and in-vivo receptor binding. Psychopharmacology 124:57-73. (Pubitemid 26112775)
39. Seeman P (2005). An update of fast-off dopamine D2 atypical antipsychotics. Am J Psychiatry 162:1984-1985. (Pubitemid 41428639)
40. Simpson GM, Angus JWS (1970). A rating scale for extrapyramidal side effect. Acta Psychiatr Scand 212 (Suppl):11-19.
41. Turkoz I, Bossie CA, Lindenmayer JP, Schooler N, Canuso CM (2011). Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis. BMC Psychiatry 7:11-21.
42. Woodward ND, Purdon SE, Meltzer HY, Zald DH (2005). A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol 23:1-16.
43. Yi JS, Ahn YM, Shin HK, An SK, Joo YH, Kim SH, et al. (2001). Reliability and validity of the Korean version of the Positive and Negative Syndrome Scale. J Korean Neuropsychiatr Assoc 40:1090-1105.